BioSpace News Archive

AQUARIUS SURGICAL TECHNOLOGIES INC. reports the results of operations for the nine-month period ended December 31, 2020.

Company adds a leading national Integrated Delivery Network (IDN) as a strategic investor. The financing supports Pear’s continued efforts to expand patient access for its portfolio of Prescription Digital Therapeutics (PDTs), including reSET®, reSET-O® and Somryst® treating addiction and insomnia conditions, respectively.

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the fourth quarter and fiscal year ended December 31, 2020 on Monday, March 8, 2021.

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the fourth quarter and full year ended December 31, 2020 on Tuesday, March 9, 2021, and host a conference call and webcast at 8:30 am Eastern Time.

DNA Script, a leading pioneer in enabling DNA on demand, shared data at this year’s Advances in Genome Biology and Technology (AGBT) General Meeting that demonstrate the comparable performance of the company’s enzymatically synthesized oligos to traditional chemically synthesized DNA in their quest to reliably support genomics and life science applications.

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced the publication of the results of both pivotal studies for PyL™

Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the publication of data highlighting the company’s original erythrocyte binding technology in Science Immunology

ATW Tech Inc. (the “Company” or “ATW Tech”) (TSX-V: ATW) is pleased to announce the appointment of Mr. Christian Trudeau as Chairman of the Board of Directors of the Company to replace Mr. Michel Guay, who was holding the position on an interim basis.

Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has entered into definitive agreements for the purchase and sale of 1,133,102 shares of Lixte’s common stock, at a purchase price of $3.70 per share, in a registered direct offering.

Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group, contributed more than $800,000 in 2020 through its Chiesi in the Community corporate social responsibility program.